OncoMatch/Clinical Trials/NCT06484556
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Is NCT06484556 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including NW-301V and NW-301D for tumor, solid.
Treatment: NW-301V · NW-301D — An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: KRAS G12V
Tumor has KRAS G12V (NW-301V cohort)
Required: KRAS G12D
Tumor has KRAS G12D (NW-301D cohort)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Adequate organ function prior to apheresis and lymphodepleting chemotherapy
Kidney function
Adequate organ function prior to apheresis and lymphodepleting chemotherapy
Liver function
Adequate organ function prior to apheresis and lymphodepleting chemotherapy
Adequate organ function prior to apheresis and lymphodepleting chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06484556 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS G12V is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS G12D is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify